BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB; Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003;22:677-86. [PMID: 12913766 DOI: 10.1097/01.inf.0000078160.29072.42] [Cited by in Crossref: 128] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 DeRonde KJ, Girotto JE, Nicolau DP. Management of Pediatric Acute Hematogenous Osteomyelitis, Part II: A Focus on Methicillin-Resistant Staphylococcus aureus, Current and Emerging Therapies. Pharmacotherapy 2018;38:1021-37. [PMID: 29989190 DOI: 10.1002/phar.2164] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
2 Stevens DL, Dotter B, Madaras-kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Review of Anti-infective Therapy 2014;2:51-9. [DOI: 10.1586/14787210.2.1.51] [Cited by in Crossref: 96] [Cited by in F6Publishing: 74] [Article Influence: 12.0] [Reference Citation Analysis]
3 Grammatikos AP, Falagas ME. Linezolid for the treatment of skin and soft-tissue infections. Expert Review of Dermatology 2014;3:539-48. [DOI: 10.1586/17469872.3.5.539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Caffrey AR, Morrill HJ, Puzniak LA, Laplante KL. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2014;34:473-80. [PMID: 24420846 DOI: 10.1002/phar.1390] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
5 Kaplan SL. Introduction. Pediatric Infectious Disease Journal 2003;22:S151-2. [DOI: 10.1097/01.inf.0000086953.15453.15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013;3:e003912. [PMID: 24127058 DOI: 10.1136/bmjopen-2013-003912] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
7 Ozkaya-Parlakay A, Kara A, Celik M, Ozsurekci Y, Karadag Oncel E, Ceyhan M, Cengiz AB. Early lactic acidosis associated with linezolid therapy in paediatric patients. Int J Antimicrob Agents 2014;44:334-6. [PMID: 25182713 DOI: 10.1016/j.ijantimicag.2014.06.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
8 Mongkolrattanothai K, Daum RS. Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children. Curr Infect Dis Rep 2005;7:381-9. [DOI: 10.1007/s11908-005-0013-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
9 Moreno RB, Rives S, Justicia A, Català A, Ruiz-llobet A, Toll T, Estella J. Successful port-a-cath salvage using linezolid in children with acute leukemia: Linezolid Use to Avoid Central Catheter Removal. Pediatr Blood Cancer 2013;60:E103-5. [DOI: 10.1002/pbc.24520] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Weisman LE. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient: . Current Opinion in Infectious Diseases 2004;17:237-41. [DOI: 10.1097/00001432-200406000-00011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
11 Bizzarro MJ, Gallagher PG. Antibiotic-Resistant Organisms in the Neonatal Intensive Care Unit. Seminars in Perinatology 2007;31:26-32. [DOI: 10.1053/j.semperi.2007.01.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
12 Kaplan SL. Challenges in the Evaluation and Management of Bone and Joint Infections and the Role of New Antibiotics for Gram Positive Infections. In: Finn A, Curtis N, Pollard AJ, editors. Hot Topics in Infection and Immunity in Children V. New York: Springer US; 2009. pp. 111-20. [DOI: 10.1007/978-0-387-79838-7_10] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
13 Milstone AM, Dick J, Carson B, Siberry GK. Cerebrospinal fluid penetration and bacteriostatic activity of linezolid against Enterococcus faecalis in a child with a ventriculoperitoneal shunt infection. Pediatr Neurosurg 2007;43:406-9. [PMID: 17786008 DOI: 10.1159/000106392] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
14 Korang SK, Nava C, Mohana SP, Nygaard U, Jakobsen JC. Antibiotics for hospital-acquired pneumonia in neonates and children. Cochrane Database Syst Rev 2021;11:CD013864. [PMID: 34727368 DOI: 10.1002/14651858.CD013864.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist 2012;5:87-102. [PMID: 22787406 DOI: 10.2147/IDR.S25890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
16 Chiappini E, Conti C, Galli L, de Martino M. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010;32:66-88. [PMID: 20171414 DOI: 10.1016/j.clinthera.2010.01.019] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
17 van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 2012;25:362-86. [PMID: 22491776 DOI: 10.1128/CMR.05022-11] [Cited by in Crossref: 445] [Cited by in F6Publishing: 223] [Article Influence: 44.5] [Reference Citation Analysis]
18 Kaplan SL, Afghani B, Lopez P, Wu E, Fleishaker D, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2003;22:S178-85. [PMID: 14520144 DOI: 10.1097/01.inf.0000087020.75886.93] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
19 Yamada K, Namikawa H, Fujimoto H, Nakaie K, Takizawa E, Okada Y, Fujita A, Kawaguchi H, Nakamura Y, Abe J, Kaneko Y, Kakeya H. Clinical Characteristics of Methicillin-resistant Coagulase-negative Staphylococcal Bacteremia in a Tertiary Hospital. Intern Med 2017;56:781-5. [PMID: 28381743 DOI: 10.2169/internalmedicine.56.7715] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
20 Bradley JS. New antibiotics for Gram-positive infections. Adv Exp Med Biol 2006;582:151-65. [PMID: 16802626 DOI: 10.1007/0-387-33026-7_13] [Reference Citation Analysis]
21 Kaplan SL. Treatment of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections. Pediatric Infectious Disease Journal 2005;24:457-8. [DOI: 10.1097/01.inf.0000164162.00163.9d] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
22 Paul IM. Advances in Pediatric Pharmacology, Therapeutics, and Toxicology. Advances in Pediatrics 2005;52:321-65. [DOI: 10.1016/j.yapd.2005.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Bosheva M, Gujabidze R, Károly É, Nemeth A, Saulay M, Smart JI, Hamed KA. A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients. Pediatr Infect Dis J 2021;40:e222-9. [PMID: 33480665 DOI: 10.1097/INF.0000000000003077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Korang SK, Safi S, Nava C, Gordon A, Gupta M, Greisen G, Lausten-Thomsen U, Jakobsen JC. Antibiotic regimens for early-onset neonatal sepsis. Cochrane Database Syst Rev 2021;5:CD013837. [PMID: 33998666 DOI: 10.1002/14651858.CD013837.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Review of Anti-infective Therapy 2014;4:947-52. [DOI: 10.1586/14787210.4.6.947] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
26 Le J, Lieberman JM. Management of Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Children. Pharmacotherapy 2006;26:1758-70. [DOI: 10.1592/phco.26.12.1758] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
27 Caffrey AR, Morrill HJ, Puzniak LA, LaPlante KL. Predictors of clinical success among a national Veterans Affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2014;36:552-9. [PMID: 24631473 DOI: 10.1016/j.clinthera.2014.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Travaglianti M, Pérez M, Sberna N, Rousseau M, Calle G, Gómez S. Tratamiento de infecciones por Enterococcus resistente a vancomicina con linezolid en un hospital pediátrico. Farmacia Hospitalaria 2007;31:43-7. [DOI: 10.1016/s1130-6343(07)75710-0] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
29 Herrmann DJ, Peppard WJ, Ledeboer NA, Theesfeld ML, Weigelt JA, Buechel BJ. Linezolid for the treatment of drug-resistant infections. Expert Rev Anti Infect Ther 2008;6:825-48. [PMID: 19053895 DOI: 10.1586/14787210.6.6.825] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
30 Sauberan JB, Bradley JS. Antimicrobial Agents. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 1499-1531.e3. [DOI: 10.1016/b978-0-323-40181-4.00292-9] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Pope SD, Roecker AM. Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections. Expert Opin Pharmacother 2007;8:1245-61. [PMID: 17563260 DOI: 10.1517/14656566.8.9.1245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
32 Gold HS, Pillai SK. Antistaphylococcal Agents. Infectious Disease Clinics of North America 2009;23:99-131. [DOI: 10.1016/j.idc.2008.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
33 Ioannidou M, Apostolidou-kiouti F, Haidich A, Niopas I, Roilides E. Efficacy and safety of linezolid for the treatment of infections in children: a meta-analysis. Eur J Pediatr 2014;173:1179-86. [DOI: 10.1007/s00431-014-2307-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
34 Fu J, Ye X, Chen C, Chen S. The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One 2013;8:e58240. [PMID: 23484002 DOI: 10.1371/journal.pone.0058240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
35 Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials. Diabetes Research and Clinical Practice 2008;80:344-51. [DOI: 10.1016/j.diabres.2008.01.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
36 Simon A, Müllenborn E, Prelog M, Schenk W, Holzapfel J, Ebinger F, Klabunde-cherwon A, Faber J, Groll AH, Masjosthusmann K, Dohna-schwake C, Beutel K, Dirkwinkel E, Lehrnbecher T, Ammann RA, Müller A. Use of linezolid in neonatal and pediatric inpatient facilities—results of a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2012;31:1435-42. [DOI: 10.1007/s10096-011-1461-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
37 Long CB, Madan RP, Herold BC. Diagnosis and management of community-associated MRSA infections in children. Expert Rev Anti Infect Ther 2010;8:183-95. [PMID: 20109048 DOI: 10.1586/eri.09.127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
38 Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, Dong W, Xing J, Dong Y. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol 2015;71:107-15. [PMID: 25355172 DOI: 10.1007/s00228-014-1775-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
39 Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opinion on Pharmacotherapy 2007;8:2381-400. [DOI: 10.1517/14656566.8.14.2381] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
40 Wang GF, Ren JA, Jiang J, Fan CG, Wang XB, Li JS. Catheter-related infection in gastrointestinal fistula patients. World J Gastroenterol 2004; 10(9): 1345-1348 [PMID: 15112356 DOI: 10.3748/wjg.v10.i9.1345] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
41 Bradley JS. Newer antistaphylococcal agents. Curr Opin Pediatr 2005;17:71-7. [PMID: 15659968 DOI: 10.1097/01.mop.0000151555.17799.41] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
42 Daum RS. Staphylococcus aureus. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 692-706.e4. [DOI: 10.1016/b978-0-323-40181-4.00115-8] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
43 Downes KJ, Hahn A, Wiles J, Courter JD, Vinks AA. Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. Int J Antimicrob Agents 2014;43:223-30. [PMID: 24389079 DOI: 10.1016/j.ijantimicag.2013.11.006] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
44 Kaplan SL. Implications of methicillin-resistant Staphylococcus aureus as a community-acquired pathogen in pediatric patients. Infect Dis Clin North Am 2005;19:747-57. [PMID: 16102659 DOI: 10.1016/j.idc.2005.05.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
45 Sáez-llorens X, Mccracken GH. Clinical Pharmacology of Antibacterial Agents. Infectious Diseases of the Fetus and Newborn Infant. Elsevier; 2006. pp. 1223-67. [DOI: 10.1016/b0-72-160537-0/50039-6] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
46 Kocher S, Müller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review. International Journal of Antimicrobial Agents 2010;36:106-10. [DOI: 10.1016/j.ijantimicag.2010.03.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
47 Avedissian SN, Rhodes NJ, Shaffer CL, Tran L, Bradley JS, Le J. Antimicrobial prescribing for treatment of serious infections caused by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in pediatrics: an expert review. Expert Rev Anti Infect Ther 2021;19:1107-16. [PMID: 33554692 DOI: 10.1080/14787210.2021.1886923] [Reference Citation Analysis]
48 Korang SK, Safi S, Nava C, Greisen G, Gupta M, Lausten-Thomsen U, Jakobsen JC. Antibiotic regimens for late-onset neonatal sepsis. Cochrane Database Syst Rev 2021;5:CD013836. [PMID: 33998665 DOI: 10.1002/14651858.CD013836.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Fergie J, Purcell K. The Treatment of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infections. Pediatric Infectious Disease Journal 2008;27:67-8. [DOI: 10.1097/inf.0b013e31816087a7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
50 Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59 Suppl 1:S59-S74. [PMID: 19766891 DOI: 10.1016/s0163-4453(09)60009-8] [Cited by in Crossref: 115] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
51 Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin Pediatr Infect Dis 2006;17:113-9. [PMID: 16934705 DOI: 10.1053/j.spid.2006.06.004] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
52 Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66. [PMID: 18156089 DOI: 10.1016/S1473-3099(07)70312-2] [Cited by in Crossref: 109] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
53 Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, Smith PB, Rodriguez W. Drug labeling and exposure in neonates. JAMA Pediatr 2014;168:130-6. [PMID: 24322269 DOI: 10.1001/jamapediatrics.2013.4208] [Cited by in Crossref: 71] [Cited by in F6Publishing: 53] [Article Influence: 8.9] [Reference Citation Analysis]
54 Marcinak JF, Frank AL. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children. Expert Review of Anti-infective Therapy 2014;4:91-100. [DOI: 10.1586/14787210.4.1.91] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
55 Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis*: . Critical Care Medicine 2010;38:1802-8. [DOI: 10.1097/ccm.0b013e3181eb3b96] [Cited by in Crossref: 68] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
56 Meissner HC, Townsend T, Wenman W, Kaplan SL, Morfin MR, Edge-padbury B, Naberhuis-stehouwer S, Bruss JB. Hematologic effects of linezolid in young children. Pediatric Infectious Disease Journal 2003;22:S186-92. [DOI: 10.1097/01.inf.0000087021.20838.d9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
57 Gurusamy KS, Koti R, Toon CD, Wilson P, Davidson BR. Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds. Cochrane Database Syst Rev 2013;:CD010427. [PMID: 24242704 DOI: 10.1002/14651858.CD010427.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
58 Moschovi M, Trimis G, Tsotra M, Chatzi F, Karamolegou K, Santou A, Tourkantoni N, Chrousos G. Efficacy and safety of linezolid in immunocompromised children with cancer. Pediatr Int 2010;52:694-8. [PMID: 20149126 DOI: 10.1111/j.1442-200X.2010.03097.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
59 Garazzino S, Tovo PA. Clinical experience with linezolid in infants and children. J Antimicrob Chemother 2011;66 Suppl 4:iv23-41. [PMID: 21521704 DOI: 10.1093/jac/dkr074] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
60 Dotis J, Iosifidis E, Ioannidou M, Roilides E. Use of linezolid in pediatrics: a critical review. International Journal of Infectious Diseases 2010;14:e638-48. [DOI: 10.1016/j.ijid.2009.10.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
61 Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J 2010;29:827-30. [PMID: 20442688 DOI: 10.1097/INF.0b013e3181df4b9a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
62 Metaxas EI, Falagas ME. Update on the safety of linezolid. Expert Opinion on Drug Safety 2009;8:485-91. [DOI: 10.1517/14740330903049706] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
63 Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol 2014;7:327-40. [PMID: 24716805 DOI: 10.1586/17512433.2014.909281] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
64 Shibata Y, Yamagishi Y, Mikamo H, Kato H, Nishiyama N, Asai N, Koizumi Y, Matsuura K, Suematsu H, Hagihara M. Comparative study on safety of linezolid and vancomycin in the treatment of infants and neonates for Gram-positive bacterial infections. Journal of Infection and Chemotherapy 2018;24:695-701. [DOI: 10.1016/j.jiac.2018.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
65 Singer J, Dowler M, Bosscher B. Emergency Department Perspective on Methicillin-resistant Staphylococcus aureus: . Pediatric Emergency Care 2006;22:270-6. [DOI: 10.1097/01.pec.0000214595.16380.c1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Schoot RA, van Dalen EC, van Ommen CH, van de Wetering MD. Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer. Cochrane Database Syst Rev 2013;:CD008975. [PMID: 23799867 DOI: 10.1002/14651858.CD008975.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
67 Jantausch BA, Deville J, Adler S, Morfin MR, Lopez P, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. Pediatr Infect Dis J 2003;22:S164-71. [PMID: 14520142 DOI: 10.1097/01.inf.0000086956.45566.55] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
68 Garazzino S, Krzysztofiak A, Esposito S, Castagnola E, Plebani A, Galli L, Cellini M, Lipreri R, Scolfaro C, Bertaina C, Calitri C, Bozzola E, Lancella L, Quondamcarlo A, Bosis S, Pugni L, Losurdo G, Soresina A, De Gaudio M, Mariotti I, Mancini L, Gabiano C, Tovo PA. Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. J Antimicrob Chemother 2011;66:2393-7. [PMID: 21764828 DOI: 10.1093/jac/dkr285] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
69 Sicard M, Launay E, Caillon J, Jacqueline C, Legrand A, Deslandes G, Navas D, Rozé J, Guen CG. Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. Eur J Clin Pharmacol 2015;71:611-5. [DOI: 10.1007/s00228-015-1813-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
70 Sandberg A, Jensen KS, Baudoux P, Van Bambeke F, Tulkens PM, Frimodt-Møller N. Intra- and extracellular activity of linezolid against Staphylococcus aureus in vivo and in vitro. J Antimicrob Chemother 2010;65:962-73. [PMID: 20211859 DOI: 10.1093/jac/dkq052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
71 Blumer J. Treatment of pediatric Gram-positive multidrug-resistant infections. Journal of Infection 2009;59:S51-8. [DOI: 10.1016/s0163-4453(09)60008-6] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
72 Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis 2013;32:1121-8. [PMID: 23568605 DOI: 10.1007/s10096-013-1867-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
73 Chen Y, Yang XY, Zeckel M, Killian C, Hornbuckle K, Regev A, Voss S. Risk of Hepatic Events in Patients Treated with Vancomycin in Clinical Studies: A Systematic Review and Meta-Analysis. Drug Safety 2011;34:73-82. [DOI: 10.2165/11539560-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
74 Li SC, Ye Q, Xu H, Zhang L, Wang Y. Population Pharmacokinetics and Dosing Optimization of Linezolid in Pediatric Patients. Antimicrob Agents Chemother 2019;63:e02387-18. [PMID: 30642929 DOI: 10.1128/AAC.02387-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7:629-641. [PMID: 19680247 DOI: 10.1038/nrmicro2200] [Cited by in Crossref: 1388] [Cited by in F6Publishing: 1308] [Article Influence: 106.8] [Reference Citation Analysis]
76 Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010;35:3-12. [PMID: 19900794 DOI: 10.1016/j.ijantimicag.2009.09.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
77 Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-padbury B, Naberhuis-stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. Pediatric Infectious Disease Journal 2003;22:S158-63. [DOI: 10.1097/01.inf.0000086955.93702.c7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 55] [Article Influence: 3.8] [Reference Citation Analysis]
78 Alshengeti A, Alamri R, Tharwat R, Alahmadi H, Alawfi A, Arkoubi M, Alrashidi Y. An Unusual Presentation of Community-Acquired Methicillin-Resistant Staphylococcus aureus Infection in a Child Treated With Linezolid. Cureus 2021;13:e18830. [PMID: 34671513 DOI: 10.7759/cureus.18830] [Reference Citation Analysis]
79 Ijzerman MM, Tack KJ, Huang DB. Combined retrospective analysis of seven phase II and III trials of the efficacy of linezolid in the treatment of pneumonia caused by multidrug-resistant Streptococcus pneumoniae. Clin Ther 2010;32:2198-206. [PMID: 21316536 DOI: 10.1016/S0149-2918(11)00023-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Sinaniotis CA, Sinaniotis AC. Community-acquired pneumonia in children. Curr Opin Pulm Med 2005;11:218-25. [PMID: 15818183 DOI: 10.1097/01.mcp.0000159831.82529.85] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
81 Sicard M, Moussa A, Barrington K, Martin B, Luu TM, Ting JY, Roberts A, Paquette V, Shah PS, Kelly E, Autmizguine J. Neonatal and Neurodevelopmental Outcomes Following Linezolid for Coagulase-negative Staphylococcal Infection: Real World Evidence. Pediatr Infect Dis J 2020;39:598-603. [PMID: 32091496 DOI: 10.1097/INF.0000000000002619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Dutronc H, Bocquentin F, Galpérine T, Lafarie-Castet S, Dupon M. [Linezolid, the first oxazolidinone antibiotic]. Med Mal Infect 2005;35:427-34. [PMID: 16297585 DOI: 10.1016/j.medmal.2005.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
83 Arrieta AC, Ang JY, Espinosa C, Fofanov O, Tøndel C, Chou MZ, De Anda CS, Kim JY, Li D, Sabato P, Sears PS, Bradley JS. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. Pediatr Infect Dis J 2021;40:317-23. [PMID: 33710976 DOI: 10.1097/INF.0000000000003030] [Reference Citation Analysis]
84 Butler KM. Enterococcal Infection in Children. Seminars in Pediatric Infectious Diseases 2006;17:128-39. [DOI: 10.1053/j.spid.2006.06.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
85 Hapnes N, Twomey A, Knowles S. Persistent vancomycin and high-level gentamicin-resistant Enterococcus faecium bacteremia and intra-aortic thrombus in an extremely low birth-weight infant. J Perinatol 2009;29:66-8. [DOI: 10.1038/jp.2008.137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
86 Castagnola E, Bandettini R, Lorenzi I, Caviglia I, Macrina G, Tacchella A. Catheter-related bacteremia caused by methicillin-resistant coagulase negative staphylococci with elevated minimal inhibitory concentration for vancomycin. Pediatr Infect Dis J 2010;29:1047-8. [PMID: 20581735 DOI: 10.1097/INF.0b013e3181e8b74d] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Falagas ME, Vardakas KZ. Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections: . Drug Safety 2008;31:753-68. [DOI: 10.2165/00002018-200831090-00004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
88 Folgori L, Bielicki J, Ruiz B, Turner MA, Bradley JS, Benjamin DK Jr, Zaoutis TE, Lutsar I, Giaquinto C, Rossi P, Sharland M. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infect Dis 2016;16:e178-89. [PMID: 27375212 DOI: 10.1016/S1473-3099(16)00069-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
89 Tamma PD, Hsu AJ. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children. Curr Opin Infect Dis 2014;27:517-27. [PMID: 25313503 DOI: 10.1097/QCO.0000000000000115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Deville JG, Goldfarb J, Kaplan SL, Equils O, Huang DB, Ang JY, Salazar JC. The use of linezolid in the treatment of paediatric patients with infections caused by enterococci including strains resistant to vancomycin. Journal of Antimicrobial Chemotherapy 2010;65:2267-70. [DOI: 10.1093/jac/dkq300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
91 Tan TQ, Yogev R. Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent. Expert Review of Clinical Pharmacology 2014;1:479-89. [DOI: 10.1586/17512433.1.4.479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
92 Perencevich EN, Harris AD, Kaye KS, Bradham DD, Fisman DN, Liedtke LA, Strausbaugh LJ; Infectious Diseases Society of America Emerging Infections Network. Physicians' acceptable treatment failure rates in antibiotic therapy for coagulase-negative staphylococcal catheter-associated bacteremia: implications for reducing treatment duration. Clin Infect Dis 2005;41:1734-41. [PMID: 16288397 DOI: 10.1086/498116] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
93 Kaplan SL. Osteomyelitis in children. Infect Dis Clin North Am 2005;19:787-97, vii. [PMID: 16297732 DOI: 10.1016/j.idc.2005.07.006] [Cited by in Crossref: 79] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
94 Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46 Suppl 5:S368-77. [PMID: 18462092 DOI: 10.1086/533593] [Cited by in Crossref: 161] [Cited by in F6Publishing: 143] [Article Influence: 11.5] [Reference Citation Analysis]
95 Newland JG, Kearns GL. Treatment Strategies for Methicillin-Resistant Staphylococcus aureus Infections in Pediatrics: . Pediatric Drugs 2008;10:367-78. [DOI: 10.2165/0148581-200810060-00004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Venkatesh MP, Placencia F, Weisman LE. Coagulase-negative staphylococcal infections in the neonate and child: an update. Semin Pediatr Infect Dis 2006;17:120-7. [PMID: 16934706 DOI: 10.1053/j.spid.2006.06.005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
97 Saiman L, Goldfarb J, Kaplan SA, Wible K, Edge-padbury B, Naberhuis-stehouwer S, Bruss JB. Safety and tolerability of linezolid in children. Pediatric Infectious Disease Journal 2003;22:S193-200. [DOI: 10.1097/01.inf.0000087022.58089.d8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
98 Tan TQ. Update on the Use of Linezolid: A Pediatric Perspective. Pediatric Infectious Disease Journal 2004;23:955-6. [DOI: 10.1097/01.inf.0000142502.13252.20] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
99 Wald-Dickler N, Holtom PD, Phillips MC, Centor RM, Lee RA, Baden R, Spellberg B. Oral Is the New IV-Challenging Decades of Blood and Bone Infection Dogma: A Systematic Review. Am J Med 2021:S0002-9343(21)00699-9. [PMID: 34715060 DOI: 10.1016/j.amjmed.2021.10.007] [Reference Citation Analysis]
100 Pansa P, Hsia Y, Bielicki J, Lutsar I, Walker AS, Sharland M, Folgori L. Evaluating Safety Reporting in Paediatric Antibiotic Trials, 2000-2016: A Systematic Review and Meta-Analysis. Drugs 2018;78:231-44. [PMID: 29218501 DOI: 10.1007/s40265-017-0850-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
101 Langgartner M, Mutenthaler A, Haiden N, Pollak A, Berger A. Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants. BMJ Case Rep 2009;2009:bcr11. [PMID: 21686411 DOI: 10.1136/bcr.11.2008.1217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
102 Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, Versalovic J, Mason EO. Three-Year Surveillance of Community-AcquiredStaphylococcus aureus Infections in Children. Clinical Infectious Diseases 2005;40:1785-91. [DOI: 10.1086/430312] [Cited by in Crossref: 412] [Cited by in F6Publishing: 360] [Article Influence: 24.2] [Reference Citation Analysis]
103 Spellberg B, Chambers HF, Musher DM, Walsh TL, Bayer AS. Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis: A Narrative Review. JAMA Intern Med 2020;180:769-77. [PMID: 32227127 DOI: 10.1001/jamainternmed.2020.0555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
104 Yogev R, Patterson LE, Kaplan SL, Adler S, Morfin MR, Martin A, Edge-padbury B, Naberhuis-stehouwer S, Bruss JB. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatric Infectious Disease Journal 2003;22:S172-7. [DOI: 10.1097/01.inf.0000088671.35064.7c] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
105 Maltezou HC, Giamarellou H. Community-acquired methicillin-resistant Staphylococcus aureus infections. International Journal of Antimicrobial Agents 2006;27:87-96. [DOI: 10.1016/j.ijantimicag.2005.11.004] [Cited by in Crossref: 92] [Cited by in F6Publishing: 76] [Article Influence: 5.8] [Reference Citation Analysis]